Information regarding matching halt in the DiaGenic share

An important strategic focus area for DiaGenic is to supply biomarkers
for the pharmaceutical industry e.g. as presented in the Annual Report
for 2009.
Reference is made to the Annual Report for 2009 page 19: "The use of
ADtect® as a cost effective tool in clinical studies for the development
of new Alzheimer's disease medicines has been presented to major
pharmaceutical companies." An internal working document regarding one
such meeting with a leading pharmaceutical player was unfortunately made
public through a web application used by one of our advisors. The
working paper does not contain any confidential information, but
regrettably gives information concerning a meeting held with a leading
pharmaceutical company. The company has instructed our advisor not to
use this particular type of web application for work related to
DiaGenic.

Contact:
Erik Christensen MD PhD, CEO?Tel.: +47 95939918?e-mail:
erik.christensen@diagenic.com